Web: www.taiclone.com
Tel: +886-2-2735-9682
Email: order@taiclone.com

# Ganetespib

## Catalog No: tcsc0697

### Available Sizes

**Size:** 5mg

**Size:** 10mg

**Size:** 50mg

**Size:** 100mg

**Size:** 200mg

**Size:** 500mg

### Specifications

**CAS No:**
888216-25-9

**Formula:**
$C_{20}H_{20}N_4O_3$

**Pathway:**
Metabolic Enzyme/Protease;Cell Cycle/DNA Damage

**Target:**
HSP;HSP

**Purity / Grade:**
>98%

**Solubility:**
DMSO : ≥ 32 mg/mL (87.82 mM)

**Alternative Names:**
STA-9090

Web: www.taiclone.com
Tel: +886-2-2735-9682
Email: order@taiclone.com

**Observed Molecular Weight:**
364.4

## Product Description

Ganetespib is a unique non-geldanamycin heat shock protein 90 (**HSP90**) inhibitor, with antitumor activity.

IC50 & Target: HSP90[1]

***In Vitro:*** Ganetespib causes depletion of receptor tyrosine kinases, extinguishing of downstream signaling, inhibition of proliferation and induction of apoptosis with $IC_{50}$ values ranging 2-30 nM in genomically-defined NSCLC cell lines. Ganetespib is also approximately 20-fold more potent in isogenic Ba/F3 pro-B cells rendered IL-3 independent by expression of EGFR and ERBB2 mutants[1]. Ganetespib exhibits potent in vitro cytotoxicity in a range of solid and hematologic tumor cell lines, induces the degradation of known Hsp90 client proteins, displays superior potency to the ansamycin inhibitor 17-allylamino-17-demethoxygeldanamycin (17-AAG)[2]. Ganetespib is a potent HSP90 inhibitor, and shown to kill canine tumor cell lines in vitro[3]. Ganetespib possesses superior JAK/STAT inhibitory activity to both P6 and 17-AAG in terms of potency or duration of response in the HEL92.1.7 cells[4].

***In Vivo:*** Ganetespib (125 mg/kg, i.v.) accumulates in tumors relative to normal tissues and displays greater in vivo efficacy than 17-AAG without increased toxicity and inhibits proliferation and induces apoptosis in parallel with EGFR depletion in NCI-H1975 xenografts[1]. Ganetespib (100, 125, 150 mg/kg, i.v.) shows potent antitumor efficacy in solid and hematologic xenograft models of oncogene addiction, as evidenced by significant growth inhibition and/or regressions[2].